Apimeds Pharmaceuticals US (APUS) Total Liabilities (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Total Liabilities for 4 consecutive years, with $21.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 2517.44% year-over-year to $21.2 million; the trailing twelve-month figure through Jun 2026 stood at $21.2 million (up 2517.44% YoY), and the FY2025 full-year result was $10.8 million, up 690.26% from the prior year.
• Total Liabilities climbed to $21.2 million in Q2 2026 per APUS's latest filing, from $10.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $21.2 million in Q2 2026 and bottomed at $264604.0 in Q1 2024.
• Historically, Total Liabilities has averaged $4.0 million across 4 years, with a median of $1.1 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Total Liabilities climbed 4.1% in 2025, then soared 2517.44% in 2026.
• Over 4 years, Total Liabilities stood at $390207.0 in 2023, then jumped by 251.4% to $1.4 million in 2024, then soared by 690.26% to $10.8 million in 2025, then surged by 95.42% to $21.2 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $21.2 million, $10.8 million, and $1.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.